logo

Sage Therapeutics, Inc. (SAGE)



Trade SAGE now with
  Date
  Headline
2/7/2019 6:33:42 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
1/23/2019 7:05:32 AM Sage Therapeutics Appoints Elizabeth Barrett And George Golumbeski To Board
1/7/2019 7:09:31 AM Sage Therapeutics To Provide Update On Key 2019 Initiatives
1/7/2019 6:03:18 AM Sage Therapeutics Says SAGE-217 Meets Primary, Secondary Endpoints In Phase 3 Clinical Trial In Postpartum Depression
1/4/2019 6:30:38 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/20/2018 7:34:41 AM Sage Therapeutics Receives Notification Of PDUFA Extension For ZULRESSO Injection
11/6/2018 6:37:52 AM Sage Therapeutics Q3 Net Loss $122.9 Mln Vs Net Loss $73.7 Mln Last Year
11/5/2018 6:34:34 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/2/2018 7:18:32 AM Sage Therapeutics Stock Trading Halted Today; FDA Advisory Committee Meeting To Discuss ZULRESSO Injection
9/6/2018 6:36:16 AM Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/15/2018 6:00:46 AM Karuna Appoints Steven Paul As CEO
8/7/2018 6:35:06 AM Sage Therapeutics Q2 Net Loss $17.0 Mln Vs Loss Of $70.2 Mln Last Year
6/12/2018 6:32:24 AM Sage Announces Pivotal Phase 3 Trial Status For SAGE-217
5/30/2018 7:07:07 AM Sage Therapeutics: FDA Acceptance Of NDA Filing & Grant Of Priority Review For Brexanolone IV In Postpartum Depression